Insider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Sells 2,170 Shares of Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Timothy Eugene Sullivan sold 2,170 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $28.70, for a total transaction of $62,279.00. Following the transaction, the chief financial officer now directly owns 88,100 shares of the company’s stock, valued at $2,528,470. This represents a 2.40 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Apellis Pharmaceuticals Trading Down 3.1 %

NASDAQ:APLS opened at $27.69 on Wednesday. The company has a market cap of $3.44 billion, a PE ratio of -13.64 and a beta of 0.94. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The company has a 50 day simple moving average of $31.86 and a two-hundred day simple moving average of $33.48. Apellis Pharmaceuticals, Inc. has a 12 month low of $24.34 and a 12 month high of $71.90.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. During the same period in the previous year, the firm earned ($1.17) EPS. The business’s revenue was up 78.3% on a year-over-year basis. Research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.72 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on APLS shares. William Blair started coverage on Apellis Pharmaceuticals in a research report on Wednesday, October 16th. They set an “outperform” rating for the company. Scotiabank cut their target price on Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating on the stock in a research note on Wednesday, November 6th. Citigroup lowered their price target on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Mizuho dropped their price target on shares of Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating on the stock in a research note on Thursday, October 24th. Finally, HC Wainwright restated a “buy” rating and set a $57.00 price objective on shares of Apellis Pharmaceuticals in a research note on Tuesday. Eight research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $46.65.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in APLS. HighVista Strategies LLC boosted its holdings in shares of Apellis Pharmaceuticals by 4.1% in the second quarter. HighVista Strategies LLC now owns 7,566 shares of the company’s stock worth $290,000 after buying an additional 300 shares during the last quarter. Amalgamated Bank raised its position in Apellis Pharmaceuticals by 5.4% in the second quarter. Amalgamated Bank now owns 6,995 shares of the company’s stock worth $268,000 after acquiring an additional 359 shares during the period. KBC Group NV raised its position in Apellis Pharmaceuticals by 34.8% in the third quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after acquiring an additional 679 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Apellis Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock worth $130,000 after acquiring an additional 781 shares during the last quarter. Finally, Wolverine Asset Management LLC bought a new stake in shares of Apellis Pharmaceuticals during the 3rd quarter valued at $27,000. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).